Viral load assay sensitivity and low level viremia in HAART treated HIV patients

Journal of Clinical Virology

Volumn 47, Issue 4, 2010, Pages 335-339

  Verhofstede, Chris ^a   Van Wanzeele, Filip ^b   Reynaerts, Jacqueline ^a   Mangelschots, Marianne ^c   Plum, Jean ^a   Fransen, Katrien ^c  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

Cobas Ampliprep Cobas TaqMan HIV 1; HIV 1 RNA quantification; Low level viremia; Viral load assay sensitivity

Indexed keywords

ARTICLE; BIOASSAY; CONTROLLED STUDY; FALSE POSITIVE RESULT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VIREMIA; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; SENSITIVITY AND SPECIFICITY; VIRAL LOAD; VIREMIA;

EID: 77949489461     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.01.008     Document Type: Article

References (9)

1. Gatanaga H., Tsukada K., Honda H., Tanuma J., Yazaki H., Watanabe T., et al. Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor. Clinical Infectious Diseases 48 January (2) (2009) 260-262
2. Lima V., Harrigan R., and Montaner J.S.G. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. Journal of Acquired Immune Deficiency Syndromes 51 May (1) (2009) 3-6
3. Havlir D.V., Bassett R., Levitan D., Gilbert P., Tebas P., Collier A.C., et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. Journal of the American Medical Association 286 July (2) (2001) 171-179
4. Dornadula G., Zhang H., VanUitert B., Stern J., Livornese Jr. L., Ingerman M.J., et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. Journal of the American Medical Association 282 November (17) (1999) 1627-1632
5. Furtado M.R., Callaway D.S., Phair J.P., Kunstman K.J., Stanton J.L., Macken C.A., et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. New England Journal of Medicine 340 May (21) (1999) 1614-1622
6. Rebeiro P.F., Kheshti A., Bebawy S.S., Stinnette S.E., Erdem H., Tang Y.W., et al. Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clinical Infectious Diseases 47 November (10) (2008) 1354-1357
7. Manavi K. The significance of low-level plasma HIV viral load on COBAS TaqMan (R) HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor (R) monitor version 1.5. HIV Clinical Trials 9 July-August (4) (2008) 283-286
8. Oliver A.R., Pereira S.F., and Clark D.A. Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR version 1.5 conventional PCR assay. Journal of Clinical Microbiology 45 November (11) (2007) 3616-3619
9. Nettles R.E., Kieffer T.L., Kwon P., Monie D., Han Y.F., Parsons T., et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. Journal of the American Medical Association 293 February (7) (2005) 817-829